Sobi moves to Large Cap

NASDAQ OMX today announced that Swedish Orphan Biovitrum AB (publ) (Sobi) will, as per 2 January 2014, move to the Large Cap listing on the NASDAQ OMX Stockholm Stock Exchange. "The move to the Stockholm Stock Exchange Large Cap listing is an important milestone in Sobi's development," says Geoffrey McDonough, CEO at Sobi. "We will enter 2014 with the momentum of this honour, and look forward to another year with several key milestones for our company and for our community of patients and stakeholders." Sobi's current market capital is close to of SEK 18 billion and the share has risen over 80% during 2013, with several important development milestones being reached as well as new partnerships signed. --- About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com For more information - not for publication Media relations Investor relations Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor Communications Relations T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 oskar.bosson@sobi.com jorgen.winroth@sobi.com Press release (PDF): http://hugin.info/134557/R/1751148/590253.pdf This announcement is distributed by GlobeNewswire on behalf of GlobeNewswire clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Swedish Orphan Biovitrum AB (publ) via GlobeNewswire [HUG#1751148]